PMID- 29154173
OWN - NLM
STAT- MEDLINE
DCOM- 20171212
LR  - 20180104
IS  - 1879-0852 (Electronic)
IS  - 0959-8049 (Linking)
VI  - 87
DP  - 2017 Dec
TI  - Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast 
      cancer.
PG  - 164-171
LID - S0959-8049(17)31351-5 [pii]
LID - 10.1016/j.ejca.2017.10.011 [doi]
AB  - BACKGROUND: The standard treatment for patients with small, node-negative, human 
      epidermal growth factor receptor type 2 (HER2)-positive breast cancer (BC) is 
      still controversial. Our aim was to assess the prognostic role of 
      tumour-infiltrating lymphocytes (TILs) in patients with stage pT1a-b 
      HER2-positive BC. PATIENTS AND METHODS: Haematoxylin and eosin slides from 
      node-negative, pT1a-b HER2-positive BC surgical specimens were retrieved from 
      pathology archives to assess TILs and their association with outcome. RESULTS: 
      TILs were evaluated in 205 patients with HER2-positive, pT1a-b tumours, who 
      underwent breast surgery between 1997 and 2009 at the European Institute of 
      Oncology. At a median follow-up of 11 years, we did not observe any association 
      between the presence of TILs, either assessed as a continuous or 
      dichotomous variable (<50 versus >/= 50%), and outcome. Within the subgroup of 
      patients with pT1a tumours who did not receive any adjuvant therapy (36/97 
      patients), the rate of disease-free survival events was lower in 
      lymphocyte-predominant BC (LPBC) as compared with non-LPBC patients (p = 0.066). 
      CONCLUSIONS: TILs cannot be used as a prognostic biomarker in pT1a-b 
      HER2-positive BC. Additional biomarkers are needed for selecting patients with 
      stage I HER2-positive BC who candidate to adjuvant therapy de-escalation.
CI  - Copyright (c) 2017 Elsevier Ltd. All rights reserved.
FAU - Criscitiello, Carmen
AU  - Criscitiello C
AD  - Division of Early Drug Development, European Institute of Oncology, Milano, 
      Italy.
FAU - Bagnardi, Vincenzo
AU  - Bagnardi V
AD  - Division of Epidemiology and Biostatistics, European Institute of Oncology, 
      Milano, Italy; Department of Statistics and Quantitative Methods, University of 
      Milan-Bicocca, Milano, Italy.
FAU - Pruneri, Giancarlo
AU  - Pruneri G
AD  - Department of Pathology, Biobank for Translational Medicine Unit, European 
      Institute of Oncology, Italy; Department of Haematology and Oncology, University 
      of Milano, Italy.
FAU - Vingiani, Andrea
AU  - Vingiani A
AD  - Department of Pathology, Biobank for Translational Medicine Unit, European 
      Institute of Oncology, Italy.
FAU - Esposito, Angela
AU  - Esposito A
AD  - Division of Early Drug Development, European Institute of Oncology, Milano, 
      Italy.
FAU - Rotmensz, Nicole
AU  - Rotmensz N
AD  - Division of Epidemiology and Biostatistics, European Institute of Oncology, 
      Milano, Italy.
FAU - Curigliano, Giuseppe
AU  - Curigliano G
AD  - Division of Early Drug Development, European Institute of Oncology, Milano, 
      Italy; Department of Haematology and Oncology, University of Milano, Italy. 
      Electronic address: Giuseppe.curigliano@ieo.it.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20171115
PL  - England
TA  - Eur J Cancer
JT  - European journal of cancer (Oxford, England : 1990)
JID - 9005373
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/*analysis
MH  - Breast Neoplasms/chemistry/*immunology/mortality/therapy
MH  - Chemotherapy, Adjuvant
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Lymphocytes, Tumor-Infiltrating/*immunology
MH  - Mastectomy
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Predictive Value of Tests
MH  - Receptor, ErbB-2/*analysis
MH  - Risk Factors
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - HER2
OT  - Stage pT1a-b breast cancer
OT  - Tumour-infiltrating lymphocytes
EDAT- 2017/11/21 06:00
MHDA- 2017/12/13 06:00
CRDT- 2017/11/21 06:00
PHST- 2017/09/30 00:00 [received]
PHST- 2017/10/08 00:00 [accepted]
PHST- 2017/11/21 06:00 [pubmed]
PHST- 2017/12/13 06:00 [medline]
PHST- 2017/11/21 06:00 [entrez]
AID - S0959-8049(17)31351-5 [pii]
AID - 10.1016/j.ejca.2017.10.011 [doi]
PST - ppublish
SO  - Eur J Cancer. 2017 Dec;87:164-171. doi: 10.1016/j.ejca.2017.10.011. Epub 2017 Nov 
      15.